CyberKnife Radiosurgery
CyberKnife Radiosurgery
HAVE A QUESTION? Need a doctor referral? Call (843) 402-CARE

CyberKnife Patient Guide

What is CyberKnife RadioSurgery?
CyberKnife is a non-invasive alternative to surgery for the treatment of tumors anywhere in the body. The treatment delivers high doses of radiation to tumors with extreme accuracy, offering new hope to patients who have inoperable or surgically complex tumors. 

How Does CyberKnife Work?
CyberKnife combines two advanced technologies to target tumors with the most accurate radiation treatment system in the world. CyberKnife uses an advanced image-guidance system to track and verify tumor location, correcting for patient movement. In addition, a multi-jointed robotic arm provides the highest level of maneuverability available. The flexible robotic arm, along with the image-guidance system, makes it possible to access tumors that were previously unreachable and minimize damage to adjacent healthy tissue. 

Is CyberKnife Clinically Proven?
CyberKnife is based on radiation technology that has been proven for more than 30 years. Thousands of patients have successfully received CyberKnife treatments worldwide.

What Makes CyberKnife So Unique?

  • T4 Accuracy – CyberKnife is the only radiosurgery treatment system available with T4 or “Tight to the Tumor” sub-millimeter accuracy (within the width of a hair). This technology targets the tumor cells only, while nearby healthy tissue is spared.
  • Flexible – By delivering radiation beams from virtually unlimited positions, the CyberKnife system can treat tumors anywhere in the body, including the brain, spine, lung, liver, pancreas and prostate.
  • 100% Frameless – CyberKnife does not require the use of a painful headframe to prevent patient movement during treatment. The image-guidance system and robotic arm are designed to compensate for patient movement.
  • Quality of Life – As a non-invasive outpatient procedure, CyberKnife allows patients to undergo treatment without impacting normal daily activities.